A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.

Abstract:

:We report the results of a phase I dose escalation trial of the multikinase inhibitor sorafenib in relapsed and refractory acute leukemia patients using an intermittent dosing regimen. Fifteen patients with advanced leukemia (12 with acute myeloid leukemia, 2 with acute lymphoblastic leukemia, 1 with biphenotypic) and a median age of 63 (range 37-85) years were enrolled and treated on a dose escalation trial. Toxicities >or=grade 3 were present in 55% of cycles and the maximum tolerated dose (MTD) was determined to be 400 mg b.i.d. x 21 days in a 28-day cycle. Plasma inhibitory assays of kinase targets extracellular signal-regulated kinase (ERK) and FLT3-internal tandem duplication (ITD) showed excellent target inhibition, with FLT3-ITD silencing occurring below the MTD. The N-oxide metabolite of sorafenib seemed to be a more potent inhibitor of FLT3-ITD than the parent compound. Despite marked ex vivo FLT-3 ITD inhibition, no patients met the criteria for complete or partial response in this monotherapy study. Out of 15 patients, 11 experienced stable disease as best response. Although sorafenib showed only modest clinical activity as a single agent in this heavily treated population, robust inhibition of FLT3 and ERK suggests that there may be a potential important role in combination therapies.

journal_name

Leukemia

journal_title

Leukemia

authors

Pratz KW,Cho E,Levis MJ,Karp JE,Gore SD,McDevitt M,Stine A,Zhao M,Baker SD,Carducci MA,Wright JJ,Rudek MA,Smith BD

doi

10.1038/leu.2010.132

subject

Has Abstract

pub_date

2010-08-01 00:00:00

pages

1437-44

issue

8

eissn

0887-6924

issn

1476-5551

pii

leu2010132

journal_volume

24

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Correction: Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients.

    abstract::Following the publication of this article, the authors noted that Patrick M. Vanderboom was inadvertently omitted from the author list. The correct author list is as follows: Sanjay Kumar, David Murray, Surendra Dasari, Paolo Milani, David Barnidge, Benjamin Madden, Patrick M. Vanderboom, Taxiarchis Kourelis, Bonnie A...

    journal_title:Leukemia

    pub_type: 已发布勘误

    doi:10.1038/s41375-019-0405-0

    authors: Kumar S,Murray D,Dasari S,Milani P,Barnidge D,Madden B,Kourelis T,Arendt B,Merlini G,Ramirez-Alvarado M,Dispenzieri A

    更新日期:2019-04-01 00:00:00

  • Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.

    abstract::We previously identified autoantibodies to the endocytic-associated protein Huntingtin-interacting protein 1-related (HIP1R) in diffuse large B-cell lymphoma (DLBCL) patients. HIP1R regulates internalization of cell surface receptors via endocytosis, a process relevant to many therapeutic strategies including CD20 tar...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.224

    authors: Wong KK,Gascoyne DM,Brown PJ,Soilleux EJ,Snell C,Chen H,Lyne L,Lawrie CH,Gascoyne RD,Pedersen LM,Møller MB,Pulford K,Murphy D,Green TM,Banham AH

    更新日期:2014-02-01 00:00:00

  • Human bone marrow cytogenetics: growth factors stimulate metaphases for specific lineages.

    abstract::Fresh and/or frozen bone marrow cells from five healthy individuals and seven patients with myeloid leukemia were studied using growth factors and a cytogenetic technique which allows simultaneous analysis of karotype and cell lineage. Cell lineages were identified using monoclonal antibodies in an alkaline phosphatas...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Keinänen M,Bloomfield CD,Machnicki J,Griffin JD,de la Chapelle A

    更新日期:1989-06-01 00:00:00

  • Molecular mechanisms of tumor progression in chronic myeloproliferative disorders.

    abstract::We have investigated the involvement of tumor suppressor genes (p53 and RB1) and dominantly acting oncogenes (Ras family genes) in BCR/ABL positive and negative chronic myeloproliferative disorders (CMPD) at different stages of the disease, including 26 cases of BCR/ABL+ chronic myeloid leukemia (CML) blast crisis, 9 ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Gaidano G,Guerrasio A,Serra A,Rege-Cambrin G,Saglio G

    更新日期:1994-04-01 00:00:00

  • Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy.

    abstract::We investigated the effect of the histone deacetylase inhibitors (HDIs), trichostatin A and trapoxin A on leukemia cells and cell lines from the viewpoint of differentiation induction. TSA induced differentiation in erythroid cell lines by itself, whereas it synergistically enhanced the differentiation that was direct...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401508

    authors: Kosugi H,Towatari M,Hatano S,Kitamura K,Kiyoi H,Kinoshita T,Tanimoto M,Murate T,Kawashima K,Saito H,Naoe T

    更新日期:1999-09-01 00:00:00

  • OCT1 and imatinib transport in CML: is it clinically relevant?

    abstract::Imatinib is a highly effective therapy for chronic phase-chronic myeloid leukaemia (CP-CML) patients; however, responses to frontline imatinib are variable. The human organic cation transporter 1 (OCT1; SLC22A1) has been reported to be the main influx transporter involved in imatinib uptake into CML cells. Furthermore...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2015.170

    authors: Watkins DB,Hughes TP,White DL

    更新日期:2015-10-01 00:00:00

  • Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody.

    abstract::To develop an effective immunotherapy for B-lineage acute lymphoblastic leukemia (ALL), bispecific monoclonal antibodies (bsAb) were raised by cell fusion of two hybridoma cell lines secreting CD3 and CD19 antibodies. The resulting bispecific antibody contains two different specificities within a single antibody molec...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Csóka M,Strauss G,Debatin KM,Moldenhauer G

    更新日期:1996-11-01 00:00:00

  • Role for c-jun N-terminal kinase in treatment-refractory acute myeloid leukemia (AML): signaling to multidrug-efflux and hyperproliferation.

    abstract::A relationship was proved between constitutive activity of leukemic cell c-jun-N-terminal kinase (JNK) and treatment failure in AML. Specifically, early treatment failure was predicted by the presence of constitutive JNK activity. The mechanistic origins of this association was sought. A multidrug resistant leukemic c...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402457

    authors: Cripe LD,Gelfanov VM,Smith EA,Spigel DR,Phillips CA,Gabig TG,Jung SH,Fyffe J,Hartman AD,Kneebone P,Mercola D,Burgess GS,Boswell HS

    更新日期:2002-05-01 00:00:00

  • Flow cytometric analysis of intercellular adhesion between B-cell precursor acute lymphoblastic leukemic cells and bone marrow stromal cells.

    abstract::The growth of B-cell precursor acute lymphoblastic leukemic (BCP ALL) cells in vitro is dependent on interactions with bone marrow (BM) stromal cells. We have recently demonstrated that the rate of cell division of BCP ALL cells increases when cultured in direct contact with BM stromal cells. In this study we describe...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Ashley DM,Bol SJ,Tucker DP,Waugh CM,Kannourakis G

    更新日期:1995-01-01 00:00:00

  • Stimulation of leukemic myelopoiesis by P30-35 CAMAL, an inhibitor of normal myelopoiesis.

    abstract::CAMAL (common antigen in myelogenous acute leukemia) is an antigenic preparation isolated in this laboratory from the bone marrow or peripheral blood cells of persons with myeloid leukemias and shown in an immunoperoxidase slide test to be diagnostic of these leukemias. CAMAL has been shown to be inhibitory to myelopo...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Leitch HA,Buskard N,Levy JG

    更新日期:1993-09-01 00:00:00

  • Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning.

    abstract::Relapse of malignant disease remains the major complication in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after hematopoietic cell transplantation (HCT) with reduced-intensity conditioning (RIC). In this study, we investigated the predictive value of disease-specific markers (DSMs), d...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2010.283

    authors: Lange T,Hubmann M,Burkhardt R,Franke GN,Cross M,Scholz M,Leiblein S,Al-Ali HK,Edelmann J,Thiery J,Niederwieser D

    更新日期:2011-03-01 00:00:00

  • Some epidemiological features of the human T-cell lymphotropic virus type I (HTLV-I) and ATL in Nigerians.

    abstract::With a seroprevalence rate (SPR) of 6%-10% among healthy adult blood donors (ABD), Nigeria and other African locales represent an endemic zone for HTLV-I. We studied SPR in patients with leukaemia, lymphomas, solid tumours, and chronic disorders, as well as in groups of men and women with varying sexual lifestyles. Se...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Williams CK,Dada A,Blattner WA

    更新日期:1994-04-01 00:00:00

  • Expression and regulation of the evi-1 gene in the human factor-dependent leukemia cell line, UCSD/AML1.

    abstract::The human factor-dependent leukemia cell line UCSD/AML1 contains the t(3;3) (q21;q26) characteristic of the syndrome of acute leukemia with high platelets. The human homologue of the murine leukemia oncogene evi-1 was recently localized to chromosome 3q24-3q28 and transcription of evi-1 is a frequent event in mouse-re...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Oval J,Smedsrud M,Taetle R

    更新日期:1992-05-01 00:00:00

  • Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) stu

    abstract::Reliable detection of JAK2-V617F is critical for accurate diagnosis of myeloproliferative neoplasms (MPNs); in addition, sensitive mutation-specific assays can be applied to monitor disease response. However, there has been no consistent approach to JAK2-V617F detection, with assays varying markedly in performance, af...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2013.219

    authors: Jovanovic JV,Ivey A,Vannucchi AM,Lippert E,Oppliger Leibundgut E,Cassinat B,Pallisgaard N,Maroc N,Hermouet S,Nickless G,Guglielmelli P,van der Reijden BA,Jansen JH,Alpermann T,Schnittger S,Bench A,Tobal K,Wilkins B,Cu

    更新日期:2013-10-01 00:00:00

  • AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL.

    abstract::The requirement that leukemic Gata1 mutations be present in cells harboring trisomy 21 led to the discovery that overexpression of ERG drives aberrant megakaryopoiesis. Given that constitutive PI3K/AKT signaling is a frequent component of hematologic malignancies and the relationship between AKT and Notch in this line...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.33

    authors: Stankiewicz MJ,Crispino JD

    更新日期:2013-06-01 00:00:00

  • Characterisation of non-concordance in the T-cell receptor gamma chain genes at presentation and clinical relapse in acute lymphoblastic leukemia.

    abstract::We have analysed the structure of the T-cell receptor gamma chain (TCRG) genes in a panel of biopsies taken from 24 patients with acute lymphoblastic leukemia (ALL) (13 cALL, one pre-B ALL, two null ALL and eight T-ALL) at presentation and at clinical relapse. In the majority of cases (18/24) the structure of these ge...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Taylor JJ,Rowe D,Kylefjord H,Chessells J,Katz F,Proctor SJ,Middleton PG

    更新日期:1994-01-01 00:00:00

  • Clinical and pharmacokinetic studies of all-trans-retinoic acid in pediatric patients with cancer.

    abstract::This review will summarize the rationale for pursuing investigations into the use of retinoids for pediatric patients with cancer, describe the phase I results of all-trans-retinoic acid (ATRA) in children, and discuss the results of a series of preclinical and clinical pharmacokinetic studies of ATRA. The prognosis f...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:

    authors: Adamson PC

    更新日期:1994-01-01 00:00:00

  • A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.

    abstract::Clinical outcomes for multiple myeloma (MM) are highly heterogeneous and it is now clear that pivotal genetic events are the primary harbingers of such variation. These findings have broad implications for counseling, choice of therapy and the design and interpretation of clinical investigation. Indeed, as in acute le...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404516

    authors: Stewart AK,Bergsagel PL,Greipp PR,Dispenzieri A,Gertz MA,Hayman SR,Kumar S,Lacy MQ,Lust JA,Russell SJ,Witzig TE,Zeldenrust SR,Dingli D,Reeder CB,Roy V,Kyle RA,Rajkumar SV,Fonseca R

    更新日期:2007-03-01 00:00:00

  • SP/drug efflux functionality of hematopoietic progenitors is controlled by mesenchymal niche through VLA-4/CD44 axis.

    abstract::Hematopoiesis is orchestrated by interactions between hematopoietic stem/progenitor cells (HSPCs) and stromal cells within bone marrow (BM) niches. Side population (SP) functionality is a major characteristic of HSPCs related to quiescence and resistance to drugs and environmental stresses. At steady state, SP cells a...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.256

    authors: Malfuson JV,Boutin L,Clay D,Thépenier C,Desterke C,Torossian F,Guerton B,Anginot A,de Revel T,Lataillade JJ,Le Bousse-Kerdilès MC

    更新日期:2014-04-01 00:00:00

  • A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.

    abstract::The study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patients with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Eight hundred and six untreated patients in the UK NCRI AML16 trial with AML/high-risk MDS (median age, 67 years; range 56-84) and norm...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.225

    authors: Burnett AK,Russell NH,Hills RK,Kell J,Nielsen OJ,Dennis M,Cahalin P,Pocock C,Ali S,Burns S,Freeman S,Milligan D,Clark RE

    更新日期:2017-02-01 00:00:00

  • Deletions on der(9) chromosome in adult Ph-positive acute lymphoblastic leukemia occur with a frequency similar to that observed in chronic myeloid leukemia.

    abstract::The t(9;22)(q34;q11), generating the Philadelphia chromosome (Ph), is found in more than 90% of patients with chronic myeloid leukemia (CML) and in 15-30% of adults with acute lymphoblastic leukemia (ALL). Different groups have recently described the presence of large genomic deletions adjacent to the translocation br...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402829

    authors: Specchia G,Albano F,Anelli L,Storlazzi CT,Zagaria A,Mancini M,Cuneo A,Pane F,Foà R,Manolelli F,Liso V,Rocchi M

    更新日期:2003-03-01 00:00:00

  • The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL.

    abstract::The R98S mutation in ribosomal protein L10 (RPL10 R98S) affects 8% of pediatric T-cell acute lymphoblastic leukemia (T-ALL) cases, and was previously described to impair cellular proliferation. The current study reveals that RPL10 R98S cells accumulate reactive oxygen species which promotes mitochondrial dysfunction a...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0176-z

    authors: Kampen KR,Sulima SO,Verbelen B,Girardi T,Vereecke S,Rinaldi G,Verbeeck J,Op de Beeck J,Uyttebroeck A,Meijerink JPP,Moorman AV,Harrison CJ,Spincemaille P,Cools J,Cassiman D,Fendt SM,Vermeersch P,De Keersmaecker K

    更新日期:2019-02-01 00:00:00

  • Molecular characterization of jumping translocations reveals spatial and temporal breakpoint heterogeneity.

    abstract::Jumping translocations (JT) are characterized by the relocalization of the same part of a donor to several recipient chromosomes. Although JT occasionally are constitutional, most are associated with hematologic malignancies. In such cases, JT usually arise during disease progression and are associated with poor progn...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401108

    authors: Andreasson P,Höglund M,Jonson T,Békàssy A,Mitelman F,Johansson B

    更新日期:1998-09-01 00:00:00

  • All-trans retinoic acid induces monocyte growth factor receptor (c-fms) gene expression in HL-60 leukemia cells.

    abstract::All-trans-retinoic (ATRA) treatment of patients with acute promyelocytic leukemia results in differentiation of the malignant cells and a high complete remission rate. ATRA treatment induced granulocytic differentiation in HL-60 cells as assessed by nitroblue tetrazolium (NBT) reduction, but had no effect on non-speci...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Hsu HC,Yang K,Kharbanda S,Clinton S,Datta R,Stone RM

    更新日期:1993-03-01 00:00:00

  • Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients.

    abstract::Unlike the case with thrombosis, prognostic models for survival and leukemic transformation (LT) in essential thrombocythemia (ET) are not available. Among 605 patients with ET seen at our institution and followed for a median of 84 months, 155 died and LT was documented in 20 patients (3.3%). In a multivariable analy...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404500

    authors: Gangat N,Wolanskyj AP,McClure RF,Li CY,Schwager S,Wu W,Tefferi A

    更新日期:2007-02-01 00:00:00

  • JAK inhibitors suppress t(8;21) fusion protein-induced leukemia.

    abstract::Oncogenic mutations in components of the JAK/STAT pathway, including those in cytokine receptors and JAKs, lead to increased activity of downstream signaling and are frequently found in leukemia and other hematological disorders. Thus, small-molecule inhibitors of this pathway have been the focus of targeted therapy i...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.197

    authors: Lo MC,Peterson LF,Yan M,Cong X,Hickman JH,Dekelver RC,Niewerth D,Zhang DE

    更新日期:2013-12-01 00:00:00

  • Inhibition of retinoic acid receptor signaling by Ski in acute myeloid leukemia.

    abstract::Acute myeloid leukemia (AML) is a heterogeneous disease with multiple different cytogenetic and molecular aberrations contributing to leukemic transformation. We compared gene expression profiles of 4608 genes using cDNA-arrays from 20 AML patients (nine with -7/del7q and 11 with normal karyotype) with 23 CD34+ prepar...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404093

    authors: Ritter M,Kattmann D,Teichler S,Hartmann O,Samuelsson MK,Burchert A,Bach JP,Kim TD,Berwanger B,Thiede C,Jäger R,Ehninger G,Schäfer H,Ueki N,Hayman MJ,Eilers M,Neubauer A

    更新日期:2006-03-01 00:00:00

  • Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism.

    abstract::In this study, the abilities of constitutive and conditional forms of the three Raf kinases to abrogate the cytokine dependency of FDC-P1 cells were examined. The constitutively active forms (delta) of all three Raf kinases were fused to the hormone-binding domain of the estrogen receptor (ER), rendering their activit...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401720

    authors: Hoyle PE,Moye PW,Steelman LS,Blalock WL,Franklin RA,Pearce M,Cherwinski H,Bosch E,McMahon M,McCubrey JA

    更新日期:2000-04-01 00:00:00

  • Ethnic and geographic diversity of chronic lymphocytic leukaemia.

    abstract::East Asians, Asian Indians and Amerindians have a five to ten-fold lower age-adjusted incidence rate (AAIR) of chronic lymphocytic leukaemia (CLL) compared with persons of predominately European descent. The data we review suggest a genetic rather than environmental basis for this discordance. All these populations ar...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-01057-5

    authors: Yang S,Varghese AM,Sood N,Chiattone C,Akinola NO,Huang X,Gale RP

    更新日期:2020-10-19 00:00:00

  • Proteomic analysis of the cell-surface membrane in chronic lymphocytic leukemia: identification of two novel proteins, BCNP1 and MIG2B.

    abstract::B-cell-specific plasma-membrane proteins are potential targets for either small molecule or antibody-based therapies. We have sought to annotate proteins expressed at the cell surface membrane in patients with chronic lymphocytic leukemia (CLL) using plasma-membrane-based proteomic analysis to identify previously unch...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402993

    authors: Boyd RS,Adam PJ,Patel S,Loader JA,Berry J,Redpath NT,Poyser HR,Fletcher GC,Burgess NA,Stamps AC,Hudson L,Smith P,Griffiths M,Willis TG,Karran EL,Oscier DG,Catovsky D,Terrett JA,Dyer MJ

    更新日期:2003-08-01 00:00:00